Nektar Therapeutics
NKTR
359 hedge funds and large institutions have $16.7B invested in Nektar Therapeutics in 2018 Q1 according to their latest regulatory filings, with 128 funds opening new positions, 89 increasing their positions, 124 reducing their positions, and 32 closing their positions.
300% more first-time investments, than exits
New positions opened: 128 | Existing positions closed: 32
111% more call options, than puts
Call options by funds: $355M | Put options by funds: $168M
81% more capital invested
Capital invested by funds: $9.21B → $16.7B (+$7.47B)
35% more funds holding
Funds holding: 265 → 359 (+94)
29% more funds holding in top 10
Funds holding in top 10: 14 → 18 (+4)
0.05% less ownership
Funds ownership: 6.56% → 6.51% (-0.05%)
28% less repeat investments, than reductions
Existing positions increased: 89 | Existing positions reduced: 124
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$1.1B |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$208M |
| 3 |
State Street
Boston,
Massachusetts
|
+$202M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
+$127M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$125M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$598M |
| 2 |
O
OppenheimerFunds
New York
|
-$334M |
| 3 |
PC
PointState Capital
New York
|
-$284M |
| 4 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$159M |
| 5 |
Primecap Management
Pasadena,
California
|
-$111M |
NKTR Hedge Fund Activity: Q1 2018 in Review
359 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Nektar Therapeutics (NKTR) for Q1 2018, worth a combined $16.7B — up 81% from $9.21B a quarter earlier.
Buyers outnumbered sellers: 128 funds opened new NKTR positions and 32 closed out — a net gain of 96 holders — while 89 added to existing stakes and 124 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $1.1B. The largest seller was BlackRock, cutting an estimated $598M.
- 359 institutional investors held Nektar Therapeutics (NKTR) as of Q1 2018, up from 265 in Q4 2017.
- Funds reported $16.7B of Nektar Therapeutics stock for Q1 2018, up 81% quarter-over-quarter.
- 128 funds opened new Nektar Therapeutics positions in Q1 2018 and 32 closed out, a net change of +96 holders.
- The largest Nektar Therapeutics buyer in Q1 2018 was Fidelity Investments, an estimated $1.1B added.
- The largest Nektar Therapeutics seller in Q1 2018 was BlackRock, an estimated $598M sold.
Based on aggregated 13F filings for Q1 2018.